Isabel Luther

Isabel Luther joined Pionyr Immunotherapeutics in June 2019, bringing more than 25 years of experience in clinical drug development, including over 20 years dedicated to clinical operations in oncology. Before joining Pionyr, Ms. Luther served as VP, Clinical Operations in a consulting role at Naked Biome, Inc. Prior to joining Naked Biome, Ms. Luther was Sr. Clinical Program Manager, Clinical Operations, at Gilead Sciences. At Gilead, she oversaw the development of multiple, concurrent assets in oncology, as well as managed the respective functional resources, at various phases of clinical research. Prior to Gilead, Ms. Luther served in supervisory roles at organizations including Onyx Pharmaceuticals (acquired by Amgen), Medivation (acquired by Pfizer), and Sugen (acquired by Pharmacia). Early in her career, Ms. Luther worked for CROs monitoring clinical trials in the field, beginning with her biopharmaceutical research internship at Corning-Besselaar (now Covance, Inc.). She holds a B.A. in Psychology from the University of California, Berkeley.